ProQR Therapeutics (PRQR) Notes Payables (2017 - 2021)

ProQR Therapeutics has reported Notes Payables for 5 years, with the latest figure at $5.5 million in Q4 2021.

• Quarterly Notes Payables rose 303.32% year-over-year to $5.5 million in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $5.5 million (up 303.32% YoY) and the FY2021 annual result came in at $5.6 million, up 335.68% from the prior year.
• Notes Payables rose to $5.5 million in Q4 2021 per PRQR's latest filing, from $1.4 million in the prior quarter.
• Over five years, Notes Payables peaked at $5.5 million in Q4 2021 and troughed at $200007.8 in Q2 2019.
• A 5-year average of $1.5 million and a median of $915531.6 in 2020 frame the typical range for Notes Payables.
• The sharpest annual moves came in 2019 and 2021: Notes Payables tumbled 91.62% in 2019, then soared 303.32% in 2021.
• Over 5 years, Notes Payables stood at $2.3 million in 2017, then increased by 3.43% to $2.4 million in 2018, then sank by 84.09% to $379662.5 in 2019, then jumped by 256.43% to $1.4 million in 2020, then jumped by 303.32% to $5.5 million in 2021.
• According to Business Quant data, Notes Payables over the past three periods registered $5.5 million, $1.4 million, and $1.1 million for Q4 2021, Q4 2020, and Q3 2020 respectively.